Anaplastic large cell lymphoma · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
BV-CHP Variant #01 | — | R 85 959 | 21d | ~48.2 mo | — | ~8 | ~R 687 670 PFS proxy · indirect | 2 |
DA-EPOCH Variant #01 | — | R 2 155 | 21d | — | — | ~8 | ~R 17 240 indirect | — |
CHOEP-14 Variant #01 | — | R 2 109 | 14d | — | — | ~6 | ~R 12 655 indirect | — |
CHOEP-21 Variant #01 | — | R 2 109 | 21d | — | — | ~6 | ~R 12 655 indirect | — |
CHOP Variant #20 | — | R 835 | 21d | ~15.5 mo | — | ~6 | ~R 5 011 PFS proxy · indirect | 3 |
5 of 5 regimens shown